$IMVT

Stout Jay S sold $138K of IMVT

Stout Jay S (Chief Technology Officer) sold 3,487 shares of Immunovant, Inc. (IMVT) at an average of $39.55 ($39.53–$39.99, $0.14M total) across 4 trades on 2026-07-08.

Original reporting
SEC EDGAR · Stout Jay S
Published Jul 10, 2026, 8:12 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 10, 2026, 8:13 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$IMVT
Neutral
medium confidence
Mentioned
$IMVT
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IMVTNeutralLow
01

Why it matters

The newest fact is the reported open-market sale by the CTO, including trade dates, share count, and weighted-average price.

02

Market read

Traders may monitor insider activity for sentiment, but this filing alone does not change Immunovant’s fundamentals.

03

What to watch

The article notes no pre-arranged 10b5-1 plan, but it does not provide context on compensation timing, option exercises, or prior sale patterns.

Relevance 4/10Novelty 3/10Timing: Filed 2026-07-10, reporting sales executed 2026-07-08.

Background

The article is a primary-source SEC Form 4 insider transaction disclosure for Immunovant, Inc.

Company-level read

Ticker impact

$IMVTNeutralMedium confidence
Context

Immunovant CTO Stout Jay S sold 3,487 shares in open-market transactions totaling $137,924.83 on 2026-07-08.

Expected impact

Likely limited near-term impact; any effect is more about sentiment than new information.

Evidence & confidence

The filing provides transaction size, price range, and post-sale holdings, but no operational, regulatory, or financial update for Immunovant.

Market effects

No direct sector read-across; this is an issuer-specific insider transaction.

None indicated.

None indicated.

Counterpoint

Insider sales can be driven by diversification, taxes, or pre-existing personal liquidity needs, so the signal may be overstated.

Key entities

  • Immunovant, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Stout Jay S

    Chief Technology Officer who sold 3,487 shares.

Related articles

$IMVTMed

Immunovant, Inc. (IMVT): Results of Operations and Financial Condition

Immunovant, Inc. (IMVT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991202686.htm EX-99.1 Document Exhibit 99.1 Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026 • All IMVT-1402 clinical development timelines remain on track, including ongoing studies in Graves’ disease (GD),

$IMVTMedAI 9/10

H.C. Wainwright Raises Price Target on Immunovant (IMVT) Following Positive Rheumatoid Arthritis Trial Data

H.C. Wainwright raised its Immunovant (IMVT) price target to $40 from $35 and kept a Buy rating after positive Phase 2 rheumatoid arthritis data, citing high response rates and suggesting FcRn differs from JAK/TNF therapies. It increased IMVT-1402 success odds to 55% (from 30%) and EV sales multiple to 10x (from 9x). BofA also lifted its target to $43 and peak sales forecast for IMVT-1402 to $6.8B from $5.5B.